Organisation paid for research Program year 2025 Source: CMS Open Payments

Bio Kinetic Clinical Applications LLC

Neither a doctor nor a teaching hospital

Research payments

$28,075,934

54 payments

Through program year 2025, Bio Kinetic Clinical Applications LLC is reported as receiving $28,075,934 in research payments, across 54 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $13,954,817 11
2024 Research $4,667,426 4
2023 Research $2,365,040 15
2022 Research $4,995,940 15
2021 Research $1,944,324 8
2020 Research $148,388 1

Breakdown

Who paid Research payments · program years 2020–2025
  1. Eli Lilly and Company $26,143,222 30 payments
  2. Hoffmann-La Roche Limited $1,278,705 12 payments
  3. Genentech, Inc. $370,967 5 payments
  4. F. Hoffmann-La Roche AG $247,474 4 payments
  5. AMAG Pharmaceuticals, Inc. $35,566 3 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Multiple-Dose Study to Investigate the Bioequivalence of Orforglipron (Ly3502970) Capsules and Orforglipron Tablets in Participants With Obesity Or Overweight Who Are Otherwise Healthy. $12,896,289 2 payments
  2. A Bioequivalence Study of Injections of Mirikizumab Solution Using Investigational 1-Ml and 2-Ml Pre-Filled Syringes and Investigational 1-Ml and 2-Ml Autoinjectors in Healthy Participants $2,427,423 2 payments
  3. A Bioequivalence Study of Subcutaneous Injections of Citrate-Free Mirikizumab Solution Using A 1-Ml Autoinjector and An Investigational 2-Ml Autoinjector in Healthy Participants $2,425,620 2 payments
  4. A Multiple-Ascending Dose Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Ly3537031 in Overweight and Obese Participants and Healthy Volunteers $1,718,791 3 payments
  5. Coated Tablet Bioequivalence Study $1,526,178 16 payments
  6. A Bioequivalence Study of Injections of Mirikizumab Solution Using An Investigational 1-Ml Pre-Filled Syringe and An Investigational 1-Ml Autoinjector in Healthy Participants $1,402,958 3 payments
  7. A Study on Pharmacokinetics of Remternetug Administered Subcutaneously Through An Autoinjector Versus Prefilled Syringe in Healthy Participants $1,186,564 2 payments
  8. A Bioequivalence Study of Subcutaneous Injections of Mirikizumab Reference Solution Using An Investigational 1-Ml Autoinjector and Mirikizumab Test Solution Formulation Using An Investigational 1-Ml Autoinjector in Healthy Participants $1,066,543 2 payments
  9. A Bioequivalence Study of Subcutaneous Injections of Mirikizumab Reference Solution Using An Investigational 1-Ml Autoinjector and Mirikizumab Test Solution Formulation Using An Investigational 1-Ml Autoinjector in Healthy Participants $933,897 2 payments
  10. A Phase 1, Open-Label, Single-Dose Bioequivalence Study of Injections of Lebrikizumab Using A 2-Ml Pre-Filled Syringe With Needle Safety Device and An Investigational 2-Ml Autoinjector in Healthy Participants $817,933 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record